Amedeo's Top 20

Amedeo Smart

Independent Medical Education

21 December 2019

Multidisciplinary Journal Club

  1. Younossi ZM, Ratziu V, Loomba R, Rinella M, et al.
    Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
    Lancet 2019.

  1. Schneider BJ, Ismaila N, Aerts J, Chiles C, et al.
    Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.
    J Clin Oncol 2019.

  2. Gupta RK, Lipman M, Jackson C, Sitch A, et al.
    Quantitative Interferon Gamma Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis: A Prospective Cohort Study.
    Am J Respir Crit Care Med 2019.

  3. Slamon DJ, Neven P, Chia S, Fasching PA, et al.
    Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
    N Engl J Med 2019.

  4. Joe E, Ringman JM.
    Cognitive symptoms of Alzheimer's disease: clinical management and prevention.
    BMJ 2019;367:l6217.

  1. Ghany MG, Marks KM, Morgan TR, Wyles DL, et al.
    Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
    Hepatology 2019.

  2. Modi S, Saura C, Yamashita T, Park YH, et al.
    Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
    N Engl J Med 2019.

  3. Cho JH, Lim SH, An HJ, Kim KH, et al.
    Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
    J Clin Oncol 2019.

  4. Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, et al.
    NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
    J Clin Oncol 2019.

  5. Lee YJ, Okuda Y, Sy J, Lee YK, et al.
    Ultrafiltration Rate, Residual Kidney Function, and Survival Among Patients Treated With Reduced-Frequency Hemodialysis.
    Am J Kidney Dis 2019.

  1. Kebir S, Hattingen E, Niessen M, Rauschenbach L, et al.
    Olfactory function as independent prognostic factor in glioblastoma.
    Neurology 2019.

  2. Murthy RK, Loi S, Okines A, Paplomata E, et al.
    Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
    N Engl J Med 2019.

  3. Malone S, Roy S, Eapen L, E C, et al.
    Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial.
    J Clin Oncol 2019.

  4. Brunner FJ, Waldeyer C, Ojeda F, Salomaa V, et al.
    Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium.
    Lancet 2019.

  5. Pillai RN, Fennell DA, Kovcin V, Ciuleanu TE, et al.
    Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2).
    J Clin Oncol 2019.

  1. Costagliola D, Potard V, Lang S, De Castro N, et al.
    Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
    J Infect Dis 2019.

  2. Tamura K, Imamura CK, Takano T, Saji S, et al.
    CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.
    J Clin Oncol 2019.

  3. Stanulla M, Cave H, Moorman AV.
    IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?
    Blood 2019.

  4. Vicini FA, Cecchini RS, White JR, Arthur DW, et al.
    Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
    Lancet 2019.

  5. Whelan TJ, Julian JA, Berrang TS, Kim DH, et al.
    External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
    Lancet 2019.


more..

Privacy Policy